Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00783198
Other study ID # P05233
Secondary ID 2008-003863-38MK
Status Completed
Phase Phase 2/Phase 3
First received October 30, 2008
Last updated December 16, 2015
Start date September 2009
Est. completion date May 2011

Study information

Verified date December 2015
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period. It is expected that ragweed allergic participants on one of the active arms of the trial will have decreased allergic rhinoconjunctivitis symptoms and require less allergy rescue medications during ragweed pollen season.


Recruitment information / eligibility

Status Completed
Enrollment 565
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Must have a clinical history of significant ragweed-induced allergic rhinoconjunctivitis of at least 2 years duration, with or without asthma and have received treatment during the previous RS.

- Must have a positive skin prick test response to Ambrosia artemisiifolia at Screening Visit.

- Must be positive for specific immunoglobulin E (IgE) against Ambrosia artemisiifolia at Screening Visit.

- Must have an forced expiratory volume in 1 second (FEV1) of at least 70% of predicted at Screening Visit.

- Safety laboratory tests and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor

Exclusion Criteria:

- Clinical history of symptomatic seasonal allergic rhinitis and/or asthma having received regular medication, due to another allergen during or potentially overlapping the RS.

- Clinical history of significant symptomatic perennial allergic rhinitis and/or asthma due to an allergen to which the participant is regularly exposed.

- Receipt of an immunosuppressive treatment within 3 months prior to the Screening Visit (except steroids for allergic and asthma symptoms).

- Clinical history of severe asthma.

- Asthma requiring medium or high dose inhaled corticosteroids.

- History of anaphylaxis with cardiorespiratory symptoms.

- History of chronic urticaria and angioedema.

- Clinical history of chronic sinusitis 2 years prior to the Screening Visit.

- Current severe atopic dermatitis.

- Breast-feeding, pregnant, or intending to become pregnant.

- Had previous treatment by immunotherapy with ragweed allergen or any other allergen 5 years prior to Screening Visit.

- History of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (except for Ambrosia artemisiifolia), rescue medications, or self-injectable epinephrine.

- History of self-injectable epinephrine use.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
SCH 39641 6 Amb a 1-U
SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
SCH 39641 12 Amb a 1-U
SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
Placebo
matching placebo sublingual tablets administered once daily

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type Measure Description Time frame Safety issue
Primary Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS) The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18). Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medicationwith different rescue medications being assigned different scores/dose unit. The maximum rhinoconjunctivitis DMS score was 36. The sum of the rhinoconjunctivitis DSS and DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means for DSS+DMS were converted to adjusted means based on an analysis of variance (ANOVA) model with baseline asthmatic condition, pollen region and treatment group as fixed effects. The 15-day period during the ragweed season with the highest moving pollen average No
Secondary Average Combined Rhinoconjunctivitis DSS and DMS Over the Entire RS The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18). Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medicationwith different rescue medications being assigned different scores/dose unit. The maximum rhinoconjunctivitis DMS score was 36. The sum of the rhinoconjunctivitis DSS and DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means for DSS+DMS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects. Approximately 5 weeks No
Secondary Average Rhinoconjunctivitis DSS for the Peak RS The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjuntivitis symptoms. Raw means for DSS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects. The 15-day period during the ragweed season with the highest moving pollen average No
Secondary Average Rhinoconjunctivitis DSS for the Entire RS The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjuntivitis symptoms. Raw means for DSS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects. Approximately 5 weeks No
Secondary Average Rhinoconjunctivitis DMS for the Peak RS Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medicationwith different rescue medications being assigned different scores/dose unit. The maximum rhinoconjunctivitis DMS score was 36, with a lower score indicating less rhinoconjuntivitis medication use. Raw means for DMS were converted to adjusted means based on an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects. The 15-day period during the ragweed season with the highest moving pollen average No
See also
  Status Clinical Trial Phase
Completed NCT00770315 - Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) Phase 3
Recruiting NCT06229379 - The Effects of a Large Language Model on Clinical Questioning Skills N/A
Not yet recruiting NCT03631108 - Feasibility Study and Preliminary Application Study on Iris OCTA
Completed NCT01028027 - Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Phase 3
Completed NCT00978029 - Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081) Phase 2
Completed NCT00550550 - Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) Phase 3
Completed NCT00562159 - Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) Phase 3
Withdrawn NCT02795273 - Efficacy and Safety of Grass-SPIRE Registration Study Phase 2/Phase 3
Not yet recruiting NCT01600365 - Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus Phase 3
Completed NCT00567918 - Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis Phase 3
Completed NCT04374656 - Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases
Completed NCT02472223 - Reducing Adenoviral Patient Infected Days N/A
Completed NCT00001734 - Screening for NEI Clinical Studies N/A
Completed NCT00623701 - Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation Phase 3
Completed NCT00581542 - Moxifloxacin vs. Polytrim for Conjunctivitis Phase 4
Completed NCT04287608 - Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
Completed NCT04984941 - Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients
Completed NCT01385371 - A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067) Phase 3
Completed NCT00921895 - A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis N/A